• TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple Sclerosis

    Source: Nasdaq GlobeNewswire / 18 Apr 2024 06:00:00   America/Chicago

    N/A
Share on,